Big brands score expanded listings

Posted 23 December 2024 AM

The PBAC delivered a swathe of recommendations for expanded listings in the November meeting, concluding most of them would have minimal financial impact if included in an existing RSA.

The PBAC recommended Amgen's Blincyto for treating patients with B-cell precursor acute lymphoblastic leukaemia who are MRD negative following induction chemotherapy, after deferring it at the July meeting pending advice from the TGA delegate. It's already listed for acute lymphoblastic leukaemia, and the recommendation included the new listing joining the RSA for Blincyto and Pfizer's Besponsa.

To see the whole article, please login